Aime To study the anti-C. albicans activity of baicablin,and to explore its anti-C.albicans mechanism preliminarily. Method ① The minimum inhibitory concentration (MIC) and the minimum fungicidal concentration(MFC) of baicalin against C.albicans were determined by microdilution method. ② By means of incorporation experiment of isotope-labelled precursor, the incorporation inhibitation rates of [ 3H]-TdR,[ 3H]-UdR,[ 3H]-leucine were measured after treatment with various concentrations of baicalin respectively. Result ① The MIC and MFC of baicalin (above purity 98%) against C albicans(1?107 cfu?L -1) were both 1.0 g?L -1. The MIC and MFC of baicalin (above 98% purity) against C albicans(2.5?107 cfu?L -1) both 2.0 g?L -1. ② The dose of baicalin of 0.5, 1 and 2 MIC could obviously inhibit incorporation of the precursors and there were significant differences among the inhibition rate of three precursors incorporation (P0.05). Conclusion ① Baicalin had strong anti-C albicans activity in vitro. ② Baicalin(above purity 98%) could obviously inhibit incorporation of [ 3H]-TdR, [ 3H]-UdR and [ 3H]-leucine into C albicans and the incorporation inhibition rate of [ 3H]-UdR was highest among them, suggesting that the anti-C albicans mechanism of baicalin may be involved with the inhibition of DNA, RNA and protein synthesis.

Objective To explore weekly levels of serum CA125, P and β-HCG in pregnant women of 4-12 weeks and their relations with threatened abortion. Methods A total of 270 pregnant women with threatened abortion who received pregnancy test in our hospital were selected as research subjects in this study, and they were in threatened abortion group. 30 healthy pregnant women who received pregnancy test in our hospital during the same period of time were se-lected as research controls, and they were in normal pregnancy group. All pregnant women had a gestational age of 4-12 weeks; the two groups of patients were all given chemiluminescence immunoassay to dynamically monitor the levels of serum CA125, P and β-HCG. Changes of serum CA125, P and β-HCG levels in the two groups of pregnant women were observed, analyzed and compared. Results CA125 level in the normal pregnancy group was significantly lower than that in the threatened abortion group, and the difference was statistically significant(P<0.05). Levels of P and β-HCG in the normal pregnancy group were both significantly higher than those in the threatened abortion group, and the differences were statistically significant (P<0.05). Conclusion Serum CA125, P and β-HCG in the prediction and early diagnosis of threatened abortion have significant clinical values, which are worthy of attention and promotion.

Objective To compare the clinical efficacy and safety of nilotinib and imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase ( CML-CP ) . Methods Until December 31st 2016, 18 patients using nilotinib and 83 using imatinib were recruited in our study.The efficacy and safety of two groups were evaluated .Results A total of 101 patients with CML-CP included 18 receiving nilotinib and 83 imatinib.The optimal response rates at 3, 6, 12 and 18 months in nilotinib and imatinib group were 88.9%(16/18) vs 57.3%(47/82) (P=0.012), 82.4%(14/17) vs 55.7%(44/79) (P=0.041), 9/12 vs 63.9% (39/61) (P=0.460), 6/9 vs 68.9% (31/45) (P=0.896) respectively.The optimal response rates by 3 months in low sokal risk group on nilotinib and imatinib were 9/9 vs 76.5%(26/34) (P=0.107), in intermediate and high sokal risk group were 7/8 vs 45.2%(14/31) (P=0.032).At the end of follow-up, the rate of major molecular response (MMR) in nilotinib group was 72.2%, which was higher than 56.6% in imatinib group (P=0.021).The rate of complete cytogenetic response ( CCyR ) in nilotinib group was 100%, which was higher than 71.1% in imatinib group (P =0.002).Progression free survival (PFS) rates in nilotinib and imatinib groups were 94.4%and 98.8%(P=0.019) respectively; whereas event free survival (EFS) rates were 88.9% and 48.2%(P=0.045).The incidence of drug related adverse reactions in nilotinib and imatinib was similar with only minor proportion of grade 3/4 adverse reactions .Conclusions Nilotinib achieves a deeper molecular response in a shorter time than imatinib in newly diagnosed patients with CML-CP, especially in patients with high risk outcome .Good safety is obtained in both groups so as to ensure a long-term administration and improving prognosis .

Objective To observe the influence of IL-12,IL-15 on CIK cell in the normal culture;to observe the anti-tumor effect in the circumstance of different combination of cytokines,and to provide a new insight for preparing high effective and qualified CIK cell in vitro.Methods The optimal concentrations of IL-2,IL-12 and IL-15 were determined,respectively.After the peripheral blood from healthy blood donors was collected,monocytes were selected and co-cultured with different cytokines into different groups,as group A(IL-2 normal culture group),group B(IL-2 and IL-12 group),group C(IL-2 and IL-15 group),group D(IL-2,IL-12 and IL-15 group),and group E(cytokine control group).The monocytes in different groups were calculated by globulimeter,the activity of cells was detected by Trypan blue staining,positive ratio of CD3,CD8,CD56 on the celluar membrane was detected by flow cytometry,and the anti-tumor effect of CIK to SMMC-7721 was detected by MTSmethod,inthedayof0,5,10,15,20 after the culture.Results Statistical analysis indicated that,the proliferation multiplication of CIK cells was significantly higher in group B,group C and group D after 10,15 and 20 days of culture than those in group A(P＜0.05);and group D had higher proliferation multi-plication than that of group C(P＜0.05).The percentage of CD3 + CD8 +,CD3 + CD56+ in CIK cell membrane in group B,C,D was significantly higher than that in group A after 15 and 20 days of culture (P＜0.05).The percentage of CD3+ CD8+,CD3+ CD56+ in CIK cell membrane in group D was significantly higher than that in group B after 15 and 20 days of culture (P＜0.05).The killing rate of CIK cells for liver cancer in each group at 10,15,20 days of culture was significantly higher than that of group A when the target target ratio was 5 ∶ 1 (P＜0.05).The killing rate of CIK cells for liver cancer in group D,C at 10,15,20 days of culture was significantly higher than that of group B(P＜0.05).Conclusion IL-12and IL-15 could improve the proliferation of CIK cells,and IL-15 also has the effect of enhancing CIK cells the tumor-killing to SMMC-7721 activity.

Objective: To investigate the efficiency and safety of domestic tyrosine kinase inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with chronic myeloid leukemia in chronic phase (CML-CP). Methods: A retrospective analysis of clinical data of CML-CP patients who received domestic dasatinib as second-line treatment in the CML collaborative group hospitals of Hubei province from March 2016 to July 2018 was performed. The optimal response rate, the cumulative complete cytogenetic response (CCyR), the cumulative major molecular responses (MMR), progression free survival (PFS), event free survival (EFS) and adverse effects (AEs) of the patients were assessed at 3, 6 and 12 months of treatment. Results: A total of 83 CML-CP patients were enrolled in this study. The median follow-up time was 23 months. The optimal response rates at 3, 6 and 12 months in 83 CML-CP patients treated with dasatinib were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, the cumulative CCyR and MMR rates were 65.5% (55/80) and 57.1% (48/73), respectively. The median time to achieving CCyR and MMR was 3 months. During follow-up time, the PFS rate was 94.0% (79/83) and the EFS rate was 77.4% (65/83). The most common non-hematological AEs of dasatinib were edema (32.5%), rash itching (18.1%) and fatigue (13.3%). The common hematological AEs of dasatinib were thrombocytopenia (31.3%), leukopenia (19.3%) and anemia (6.0%). Conclusion Domestic dasatinib was effective and safe as the second-line treatment of CML-CP patients and it can be used as an option for CML-CP patients.